ARK Reports 11.43% Of Beam Therapeutics — Its Stake Retains Passive Status
ARK Innovation ETF was the client identified as holding an interest above 5% in the reported shares.
ARK Investment Management reported an 11.43% stake in Beam Therapeutics, which develops gene-editing medicines, in an SEC ownership disclosure filed Friday. The investment manager retained its certification that the shares were held without a purpose of changing or influencing Beam's control.
11.8 Million Shares, Shared Reporting
ARK reported 11,805,372 common shares, with ownership measured as of September 30, 2026. ARK Innovation ETF, a fund identified as an ARK client, held an interest above 5% in those securities.
Catherine D. Wood, ARK's chief executive officer and chief investment officer, was a joint reporting person under an agreement to file with ARK. Her reporting row listed the same share count and ownership percentage.
ARK had exclusive voting authority over 11,174,409 shares and shared voting authority over 160,825. Wood's row listed shared voting authority over 11,335,234 shares. ARK had sole authority to dispose of the reported 11,805,372 shares; Wood's authority to dispose of that count was shared.
The passive certification said the securities were bought and held as part of ordinary business activity. ARK's concentrated ETF positions in small and midsize companies have produced frequent ownership reports: the firm filed about 170 such schedules in two years.
Beam's Gene-Editing Drug Pipeline
Beam's medicines use base editing, a technique that alters an individual DNA letter while leaving both strands uncut. Its lead programs address sickle cell disease and alpha-1 antitrypsin deficiency, an inherited condition that affects the lungs and liver.
The investigational sickle cell therapy, risto-cel, is being studied in an early- to mid-stage trial involving about 50 patients. BEAM-302 is a one-time treatment in clinical trials for alpha-1 antitrypsin deficiency.
Beam is also testing candidates for a rare metabolic disease associated with the liver and developing a treatment for phenylketonuria. Collaborations and licensing agreements with Pfizer, Apellis and Eli Lilly generate revenue for the company.
Beam operates a 100,000-square-foot manufacturing site in Research Triangle Park, North Carolina. Its market value was $2.5 billion in Friday trading as of 1:15 p.m. ET.
Sources
- SCHEDULE 13G/A — ARK Investment Management LLC re: Beam Therapeutics Inc. (BEAM) — SEC EDGAR
- SCHEDULE 13G/A Exhibit 1 — EXHIBIT 1 — SEC EDGAR